Skip to content

Sutimlimab exposure and hemoglobin response

A two-compartment PK/PD model coupling sutimlimab linear and nonlinear disposition to concentration-dependent recovery and turnover of hemoglobin.

Sutimlimab Pharmacokinetics and Pharmacodynamics in Patients with Cold Agglutinin Disease ↗

The Journal of Pharmacology and Experimental Therapeutics

Exploration notes · What are you exploring?

Notes stay on this browser.

MODEL IN MOTION 18 sec

How do the two body-weight regimens connect exposure and hemoglobin?

Run settings

Run location

Explore this model

Choose a scenario, adjust inputs, and run the simulation.

Approved 6.5 g regimen, 65 kg

How does sutimlimab exposure translate into the onset and maintenance of hemoglobin response?

0–25,032 hour

Scenario details

Approved 6.5 g regimen, 65 kg

How does sutimlimab exposure translate into the onset and maintenance of hemoglobin response?

Readouts

Central sutimlimab concentration · Unit unavailable
Central sutimlimab concentration over the selected simulation window.
Hemoglobin concentration · g/dL
Hemoglobin concentration over the selected simulation window.
Sutimlimab pharmacodynamic effect · Unit unavailable
Sutimlimab pharmacodynamic effect over the selected simulation window.
Exposure (AUC) · h*ug/mL
Exposure (AUC) over the selected simulation window.

Study purpose

  • How does sutimlimab exposure translate into the onset and maintenance of hemoglobin response?

Inputs changed since the displayed result. Run to update the comparison.

Loading starting example…

Edit inputs

Model parameter

Systemic clearance governing removal of modeled material from the relevant compartment.

mL/h

Suggested: 2.85–8.54. You can explore beyond this range.

5.69 → —

Central distribution volume used to convert modeled amount to concentration in the relevant compartment.

L

Suggested: 1.92–5.75. You can explore beyond this range.

3.83 → —

Maximum elimination rate coefficient used by the released system of model equations.

mg/h

Suggested: 4.93–14.8. You can explore beyond this range.

9.85 → —

Half-maximal effect concentration at which the corresponding modeled effect reaches half of its maximum.

µg/mL

Suggested: 77.5–233. You can explore beyond this range.

155 → —

Turnover time coefficient used by the released system of model equations.

h

Suggested: 94–282. You can explore beyond this range.

188 → —
Simulation time
h
h
25030 → 168

Time between reported samples.

h
24 → 1

2 changes · Variation 1

Continue in the background and keep the result.

Biology

Intravenous sutimlimab enters a central pool, exchanges with a peripheral pool, and undergoes linear plus saturable clearance. Central concentration generates an empirical Emax effect that reduces modeled hemoglobin loss, while hemoglobin production remains fixed and drug exposure accumulates.

How does sutimlimab exposure alter empirical hemoglobin turnover?Intravenous sutimlimab enters a central pool, exchanges with a peripheral pool, and undergoes linear plus saturable clearance. Central concentration generates an empirical Emax effect that reduces modeled hemoglobin loss, while hemoglobin production remains fixed and drug exposure accumulates.BIOLOGY OVERVIEWHow does sutimlimab exposure alter empirical hemoglobin turnover?IV sutimlimab: Infusion to central amountIV sutimlimabInfusion to central amountCentral exposure: Sutimlimab concentrationCentral exposureSutimlimab concentrationPeripheral pool: Reversible distributionPeripheral poolReversible distributionPK clearance: Linear and saturable lossPK clearanceLinear and saturable lossEmpirical drug effect: Concentration-dependent EmaxEmpirical drugeffectConcentration-dependent EmaxHemoglobin turnover: Drug effect reduces modeled lossHemoglobinturnoverDrug effect reduces modeledlossCumulative exposure: Central concentration integralCumulativeexposureCentral concentration integralPRIMARY READOUTSCentral sutimlimab concentrationCentral sutimlimab concent…HemoglobinHemoglobinDrug-effect fractionDrug-effect fractionCumulative exposureCumulative exposure

Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.

Model scope: An explicit C1s or classical-complement state, complement cascade, hemolysis or red-cell pools, and transfusion events are not represented; concentration acts empirically on hemoglobin loss.

Modeled relationships (6)
  • IV sutimlimab → Central exposure: IV input (flow)
  • Central exposure ↔ Peripheral pool: distribution (reversible exchange)
  • Central exposure → PK clearance: linear + saturable (loss)
  • Central exposure → Empirical drug effect: Emax effect (modulation)
  • Empirical drug effect → Hemoglobin turnover: reduces Hb loss (modulation)
  • Central exposure → Cumulative exposure: integrates C (production)

Modeled relationships: IV sutimlimab to Central exposure: IV input (flow); Central exposure reversibly exchanges with Peripheral pool: distribution (reversible exchange); Central exposure to PK clearance: linear + saturable (loss); Central exposure to Empirical drug effect: Emax effect (modulation); Empirical drug effect to Hemoglobin turnover: reduces Hb loss (modulation); Central exposure to Cumulative exposure: integrates C (production).

Primary readouts: Central sutimlimab concentration; Hemoglobin; Drug-effect fraction; Cumulative exposure.

Model details

27 parameters · 5 states · 5 equations · 9 derived outputs

Classification & API access
Therapeutic
Sutimlimab
Modality
Monoclonal antibody
Target
Complement C1s
Disease / scope
Cold agglutinin disease
ParameterDefaultUnitDescription
Ageage_year43.5yearAge coefficient used by the released system of model equations.
Below threshold transitionbelow_threshold_transition_ug_ml25µg/mLBelow threshold transition coefficient used by the released system of model equations.
Blood transfusionblood_transfusion0—Blood transfusion coefficient used by the released system of model equations.
Body weightbody_weight_kg65kgBody weight used for body-size scaling in the model.
Clcrclcr_ml_min78.03mL/minClcr coefficient used by the released system of model equations.
Is japaneseis_japanese0—Is japanese coefficient used by the released system of model equations.
Reference agereference_age_year43.5yearReference age coefficient used by the released system of model equations.
Reference body weightreference_body_weight_kg71.85kgReference body weight used for body-size scaling in the model.
Reference clcrreference_clcr_ml_min78.03mL/minuteReference clcr coefficient used by the released system of model equations.
Age effect central distribution volumetable3_age_effect_vc0.182—Age effect central distribution volume used to convert modeled amount to concentration in the relevant compartment.
Body weight on clearance exponenttable3_body_weight_on_cl_exponent1.71—Body weight on clearance exponent used for body-size scaling in the model.
Body weight on central distribution volume exponenttable3_body_weight_on_vc_exponent0.536—Body weight on central distribution volume exponent used for body-size scaling in the model.
Systemic clearancetable3_cl_ml_h5.69mL/hSystemic clearance governing removal of modeled material from the relevant compartment.
Japanese effect central distribution volumetable3_japanese_effect_vc0.285—Japanese effect central distribution volume used to convert modeled amount to concentration in the relevant compartment.
Japanese effect maximum elimination ratetable3_japanese_effect_vmax0.3—Japanese effect maximum elimination rate coefficient used by the released system of model equations.
Kmtable3_km_ug_ml8.61µg/mLKm coefficient used by the released system of model equations.
Intercompartmental clearancetable3_q_ml_h19.8mL/hIntercompartmental clearance governing exchange between model compartments.
Central distribution volumetable3_vc_l3.83LCentral distribution volume used to convert modeled amount to concentration in the relevant compartment.
Maximum elimination ratetable3_vmax_mg_h9.85mg/hMaximum elimination rate coefficient used by the released system of model equations.
Peripheral distribution volumetable3_vp_l1.98LPeripheral distribution volume used to convert modeled amount to concentration in the relevant compartment.
Clcr on HB0 exponenttable4_clcr_on_hb0_exponent0.122—Clcr on HB0 exponent coefficient used by the released system of model equations.
Half-maximal effect concentrationtable4_ec50_ug_ml155µg/mLHalf-maximal effect concentration at which the corresponding modeled effect reaches half of its maximum.
Maximum-effect logit coefficienttable4_emax_logit_parameter0.325—Maximum-effect logit coefficient defining the limiting magnitude of the corresponding pharmacodynamic effect.
HB0 g dltable4_hb0_g_dl8.99g/dLHB0 g dl coefficient used by the released system of model equations.
Transfusion effect on emax logittable4_transfusion_effect_on_emax_logit-0.631—Transfusion effect on emax logit defining the limiting magnitude of the corresponding pharmacodynamic effect.
Turnover timetable4_turnover_time_h188hTurnover time coefficient used by the released system of model equations.
Target troughtarget_trough_ug_ml100µg/mLTarget trough coefficient used by the released system of model equations.

Related models

Dupilumab exposure and atopic-dermatitis responseCharged trastuzumab ADC plasma dispositionSKB264 tumor-growth inhibitionZenocutuzumab PK and tumor-growth dynamics

Feedback: helpdesk@unibiointelligence.com.

Ubi Biologics